Reverb Therapeutics Raises $12M to Advance Amplify•R™ Platform Reverb Therapeutics, a biotechnology company pioneering innovative approaches to harness the natural immune system and cytokine signaling for the treatment of life-threatening diseases, has announced the successful closing of a $12 million…
ICC Arbitral Tribunal Decides in Favor of AOP Health in Arbitration over BESREMi® (Ropeginterferon alfa-2b) A tribunal under the International Chamber of Commerce (ICC) issued a partial final award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its…
Pneuma Respiratory: Advancing Inhaled Therapeutics to Revolutionize Respiratory Health Pneuma Respiratory, a pioneering med-tech and pharmaceutical company, is breaking new ground in the field of inhaled respiratory therapeutics. With a strong commitment to improving the standard of care for millions…
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Updates Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company dedicated to developing innovative treatments for individuals suffering from acute cannabis-induced toxic effects, has…
Newleos Launches with $93.5M to Advance Neuropsychiatric Treatments Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development, has announced the successful closing of an oversubscribed $93.5 million Series A financing. This…
Taiho Oncology Europe Announces Availability of Futibatinib in Italy for the Treatment of Cholangiocarcinoma Taiho Oncology Europe, a subsidiary of Taiho Pharmaceutical Co., Ltd., has officially announced the availability of futibatinib in Italy for the treatment of patients diagnosed with…
Incyte Announces Q4 and Full-Year 2024 Financial Results, Shares 2025 Guidance and R&D Milestones Incyte reported its financial results for the fourth quarter and full year ended December 31, 2024. The company also provided its financial outlook for 2025 and…
Bristol Myers Squibb (NYSE: BMY) has announced positive topline results from the Phase 2 TRANSCEND FL trial, evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. The study met its primary endpoint in the…
Levi & Korsinsky, LLP Announces Securities Fraud Lawsuit Against Regeneron Pharmaceuticals, Inc. Levi & Korsinsky, LLP has issued a notice to investors in Regeneron Pharmaceuticals the regarding a class action lawsuit filed against the Company. This lawsuit aims to recover…
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data for PP-007 in AIS at 2025 ISC Phase 1 Data Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, is poised to make a significant contribution to the field of acute ischemic stroke (AIS)…
LEO Pharma Reports Positive DELTA TEEN Results for Anzupgo® in Adolescent CHE LEO Pharma Reports A/S, a global leader in medical dermatology, has announced the successful completion of its DELTA TEEN trial, a pivotal phase 3 clinical study evaluating Anzupgo®…
United Therapeutics Announces Full Enrollment in TETON 1 Study of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis Inhaled Treprostinil United Therapeutics Corporation a public benefit corporation, recently announced the completion of full enrollment in its pivotal TETON 1 clinical study. This…